PLx Pharma Inc.
PLXP · NASDAQ
12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | |
|---|---|---|---|---|
| Revenue | $8 | $0 | $1 | $1 |
| % Growth | 26,873.4% | -94.6% | -24.9% | – |
| Cost of Goods Sold | $5 | $0 | $0 | $0 |
| Gross Profit | $3 | $0 | $1 | $1 |
| % Margin | 41.5% | 100% | 100% | 100% |
| R&D Expenses | $4 | $4 | $5 | $4 |
| G&A Expenses | $0 | $9 | $10 | $8 |
| SG&A Expenses | $40 | $9 | $10 | $8 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $44 | $13 | $15 | $12 |
| Operating Income | -$41 | -$13 | -$14 | -$11 |
| % Margin | -497% | -44,229.7% | -2,511.6% | -1,455.5% |
| Other Income/Exp. Net | -$5 | -$2 | -$6 | $12 |
| Pre-Tax Income | -$46 | -$15 | -$21 | $1 |
| Tax Expense | $5 | -$0 | $1 | $0 |
| Net Income | -$51 | -$15 | -$21 | $1 |
| % Margin | -626.9% | -49,631.9% | -3,773.7% | 119% |
| EPS | -2.18 | -1.55 | -2.39 | 0.1 |
| % Growth | -40.6% | 35.1% | -2,490% | – |
| EPS Diluted | -2.18 | -1.55 | -2.39 | 0.1 |
| Weighted Avg Shares Out | 24 | 10 | 9 | 9 |
| Weighted Avg Shares Out Dil | 24 | 10 | 9 | 9 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $1 | $1 |
| Depreciation & Amortization | $6 | $0 | $0 | $0 |
| EBITDA | -$35 | -$14 | -$14 | $2 |
| % Margin | -429.3% | -47,607.9% | -2,440% | 297.9% |